2000-2015年英格兰、威尔士和北爱尔兰结核病患者抗结核药物获得性耐药情况
研究分析了2000-2015年英格兰、威尔士和北爱尔兰培养确诊结核病患者中抗结核药物获得性耐药的流行病学与危险因素。获得性耐药发生率为0.2%(158/67,710),相关因素包括肺部疾病、初始异烟肼或利福平或两者耐药、既往结核病史及中国或南非出生。获得性耐药患者治疗转归更差。
要点
- 培养确诊结核患者中获得性耐药发生率为0.2%(158/67,710)。
- 肺部疾病、初始异烟肼或利福平或两者耐药、既往结核病史及中国或南非出生与获得性耐药相关。
- 获得性耐药患者治疗转归较无获得性耐药者更差。
核心结论
- 研究地区获得性耐药虽罕见,但特定患者群体风险更高。
- 识别这些患者并确保治疗资源充足可能预防耐药发生,从而限制耐药分枝杆菌传播。
研究设计与样本
- 研究分析了2000-2015年英格兰、威尔士和北爱尔兰培养确诊结核病患者中抗结核药物获得性耐药的流行病学与危险因素。
- 采用多变量逻辑回归分析相关因素。
主要发现
- 培养确诊结核患者中获得性耐药发生率为0.2%(158/67,710)。
- 与获得性耐药相关的因素包括:肺部疾病;初始异烟肼、利福平或两者耐药;既往结核病史;中国或南非出生。
- 获得性耐药患者治疗转归较无获得性耐药者更差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the treatment pathway. To improve diagnosis and care for patients with drug-resistant TB, we examined the epidemiology and risk factors associated with acquired drug resistance during 2000-2015 among TB patients in England, Wales, and Northern Ireland. We found acquired resistance in 0.2% (158/67,710) of patients with culture-confirmed TB. Using multivariate logistic regression, we identified the following factors associated with acquired drug resistance: having pulmonary disease; initial resistance to isoniazid, rifampin, or both; a previous TB episode; and being born in China or South Africa. Treatment outcomes were worse for patients with than without acquired resistance. Although acquired resistance is rare in the study area, certain patient groups are at higher risk. Identifying these patients and ensuring that adequate resources are available for treatment may prevent acquisition of resistance, thereby limiting transmission of drug-resistant strains of mycobacteria.
引用
- Loutet MG, Davidson JA, Brown T, et al. Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015. Emerg Infect Dis. 2018. PMID: 29460735. doi:10.3201/eid2403.171362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。